JonesTrading analyst Soumit Roy has reiterated their bullish stance on JANX stock, giving a Buy rating on March 6.
Soumit Roy has given his Buy rating due to a combination of factors including Janux Therapeutics’ promising technological advancements and upcoming catalysts. The company’s masking technology is showing strong potential, with best-in-class data, despite recent competitive data from peers. Janux is expected to provide updated data from their PSMA and EGFR targeting masked T cell engagers in 2025, which could further validate their technology and enhance their clinical-stage programs.
Additionally, Janux has a substantial cash position of approximately $1.03 billion, which supports their ongoing and future research and development activities. The company’s focus on moving to earlier lines of treatment and exploring different dosing regimens also contributes to a positive outlook. Although there is some competitive pressure, the analyst remains optimistic about Janux’s potential to achieve significant milestones in the near future.